Hypertension (High Blood Pressure News and Research RSS Feed - Hypertension (High Blood Pressure News and Research

CVRx receives HDE approval for Barostim neo legacy device

CVRx receives HDE approval for Barostim neo legacy device

CVRx, Inc., a privately held medical device company, announced today that it has received Humanitarian Device Exemption (HDE) approval from the U.S. Food and Drug Administration for its Barostim neo legacy device. [More]
CVRx gets CE Mark approval to expand labeling of Barostim neo System as MR Conditional

CVRx gets CE Mark approval to expand labeling of Barostim neo System as MR Conditional

CVRx, Inc., a privately held medical device company, announced today that CE Marking has been granted to expand labeling of the Barostim neo System as MR Conditional, or safe for use in Magnetic Resonance Imaging (MRI) systems under specified conditions. [More]
CVRx Barostim neo System receives CE Mark approval from NSAI for treatment of heart failure

CVRx Barostim neo System receives CE Mark approval from NSAI for treatment of heart failure

CVRx, Inc., a private medical device company, announced today it received CE Mark approval from the National Standards Authority of Ireland of the Barostim neo System for the treatment of heart failure. [More]
FDA approves Epaned for treatment of symptomatic and asymptomatic heart failure

FDA approves Epaned for treatment of symptomatic and asymptomatic heart failure

Silvergate Pharmaceuticals, Inc., focused on the development and commercialization of innovative and safe medicines for children, today announced that the United States Food and Drug Administration approved Epaned for the treatment of symptomatic heart failure and the treatment of asymptomatic left ventricular dysfunction (to decrease the rate of development of overt heart failure and to reduce hospitalization for heart failure). [More]
Measure Up/Pressure Down campaign improves high blood pressure control in 205,000 patients

Measure Up/Pressure Down campaign improves high blood pressure control in 205,000 patients

Medical groups participating in Measure Up/Pressure Down®, a national hypertension campaign, improved detection or control of high blood pressure for 205,000 Americans living with the disease in the first 12 months of the campaign, the American Medical Group Foundation (AMGF) announced today. [More]
Empagliflozin lowers blood pressure in patients with Type 2 diabetes and hypertension

Empagliflozin lowers blood pressure in patients with Type 2 diabetes and hypertension

An investigational drug to treat Type 2 diabetes, empagliflozin, lowers blood pressure in patients with Type 2 diabetes and hypertension (high blood pressure), a new study finds. [More]
Empagliflozin drug reduces blood pressure in patients with Type 2 diabetes, hypertension

Empagliflozin drug reduces blood pressure in patients with Type 2 diabetes, hypertension

An investigational drug to treat Type 2 diabetes, empagliflozin, lowers blood pressure in patients with Type 2 diabetes and hypertension (high blood pressure), a new study finds. The results were presented Sunday in a late-breaking abstract at the joint meeting of the International Society of Endocrinology and The Endocrine Society: ICE/ENDO 2014 in Chicago. [More]
New treatment for ovarian cancer can improve response rates

New treatment for ovarian cancer can improve response rates

Doctors at the University of Arizona Cancer Center at St. Joseph's Hospital and Medical Center in Phoenix reported today in Lancet Oncology that a new treatment for ovarian cancer can improve response rates (increase the rate of tumor shrinkage) and prolong the time until cancers recur. [More]
St. Jude Medical's EnligHTN renal denervation system safe, effective for treating drug-resistant hypertension

St. Jude Medical's EnligHTN renal denervation system safe, effective for treating drug-resistant hypertension

St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced preliminary results from the EnligHTN III study, which found the company's second-generation EnligHTN™ renal denervation system provided safe and effective therapy for patients with drug-resistant, uncontrolled hypertension six months post-procedure. The results were presented during a hot line late-breaking clinical trial session at EuroPCR 2014. [More]
Northwestern University awarded NIH grant to conduct phase III Parkinson's neuroprotective study

Northwestern University awarded NIH grant to conduct phase III Parkinson's neuroprotective study

Tanya Simuni, M.D., medical director of Northwestern University's Parkinson's Disease and Movement Disorders Center, was awarded a grant from the National Institutes of Health to conduct a $16 million phase III study of the safety and efficacy of the drug isradipine as a potential neuroprotective agent in Parkinson's disease. [More]
Biogen Idec's ALPROLIX gets Health Canada approval for hemophilia B

Biogen Idec's ALPROLIX gets Health Canada approval for hemophilia B

Today Biogen Idec announced that Health Canada has approved ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], for the control and prevention of bleeding episodes and routine prophylaxis in adults, and children aged 12 and older, with hemophilia B. [More]
Heavy exposure to air pollution increases risk for developing hypertension during pregnancy

Heavy exposure to air pollution increases risk for developing hypertension during pregnancy

Breathing the air outside their homes may be just as toxic to pregnant women - if not more so - as breathing in cigarette smoke, increasing a mom-to-be's risk of developing deadly complications such as preeclampsia, according to findings from a new University of Florida study. [More]
Janssen reports positive pivotal Phase 2 study data of siltuximab for Multicentric Castleman's Disease

Janssen reports positive pivotal Phase 2 study data of siltuximab for Multicentric Castleman's Disease

Janssen Research & Development, LLC today announced positive results from a pivotal Phase 2 global registration study (MCD2001) suggesting siltuximab, an investigational compound, along with best supportive care, exhibited statistically significant efficacy and a tolerable safety profile compared with placebo and BSC in treating patients with the rare disorder Multicentric Castleman's Disease who are HIV-negative and human herpes virus 8-negative. [More]
CVD expert requests Mexican government to carry out mandatory screening for 18-year-olds

CVD expert requests Mexican government to carry out mandatory screening for 18-year-olds

A cardiovascular disease expert is calling for mandatory screening of 18 year-old Mexicans to halt the CVD epidemic plaguing the nation. Cardiovascular risk factors will be a key theme at the Mexican Congress of Cardiology, held 23 to 27 November in Leon, Guanajuato, Mexico. The Congress is organised by the Mexican Society of Cardiology and features a collaborative programme with the European Society of Cardiology. [More]
Hypertension during pregnancy could raise woman's lifetime risk of stroke

Hypertension during pregnancy could raise woman's lifetime risk of stroke

High blood pressure during pregnancy could dramatically raise a woman's lifetime risk of stroke, according to a study presented today at the Canadian Stroke Congress. [More]
Moderate coffee consumption unlikely to adversely affect cardiovascular health

Moderate coffee consumption unlikely to adversely affect cardiovascular health

Coffee is one of the most extensively researched components in the diet. New studies are regularly being added to the already large body of scientific research, which overall suggests that moderate habitual coffee consumption is not associated with detrimental effects on cardiovascular health. [More]
Prolonged use of calcium-channel blocker to treat BP linked with high breast cancer risk

Prolonged use of calcium-channel blocker to treat BP linked with high breast cancer risk

Long-term use of a calcium-channel blocker to treat hypertension (high blood pressure) is associated with higher breast cancer risk, according to a report published by JAMA Internal Medicine, a JAMA Network publication. [More]
CVRx enrolls first patient in Barostim HOPE4HF clinical trial

CVRx enrolls first patient in Barostim HOPE4HF clinical trial

CVRx, Inc., a private medical device company, announced the first patient enrolled in the Barostim HOPE4HF clinical trial. The study is evaluating the effectiveness and safety of CVRx's Barostim neo in heart failure patients. [More]
Fibromyalgia: an interview with Dr Frederick Wolfe, University of Kansas School of Medicine

Fibromyalgia: an interview with Dr Frederick Wolfe, University of Kansas School of Medicine

Fibromyalgia is a common disorder that is diagnosed in people who have pain in many areas of their body together with important symptoms such as... [More]
Eating diets high in sugar and fat may not affect health outcomes of older adults

Eating diets high in sugar and fat may not affect health outcomes of older adults

Eating diets high in sugar and fat may not affect the health outcomes of older adults ages 75 and up, suggesting that placing people of such advanced age on overly restrictive diets to treat their excess weight or other conditions may have little benefit, according to researchers at Penn State and Geisinger Healthcare System. [More]